Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Mayne Pharma Group Limited
  6. Company
    MYX   AU000000MYX0

MAYNE PHARMA GROUP LIMITED

(MYX)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Mayne Pharma Group Ltd is an Australia-based specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals. The CompanyÔÇÖs segments include Generic Products (GPD), Specialty Products (SPD), Metrics Contract Services (MCS), and Mayne Pharma International (MPI). The GPD segment is engaged in the distribution of generic pharmaceutical products in the United States. GPD segment engaged in the distribution of generic pharmaceutical products in the United States. MCS segment is providing contract pharmaceutical development and manufacturing services to third party customers principally in the United States. SPD segment is distributing specialty pharmaceutical products in the United States. MPI segment manufactures and sells branded and generic pharmaceutical products globally and provisions of contract manufacturing services to third party customers within Australia.
Sales per Business
20202021Delta
Generic Products253.0555.4%204.6051.1% -19.14%
Metrics Contract Services82.8218.1%82.0920.5% -0.89%
Specialty Products78.7617.2%71.3417.8% -9.43%
Mayne Pharma International42.369.3%42.7610.7% +0.95%
AUD in Million
Sales per region
20202021Delta
United States414.6390.7%358.0289.3% -13.65%
Australia28.246.2%29.827.4% +5.59%
Other9.312%7.781.9% -16.47%
Asia4.801.1%5.161.3% +7.47%
AUD in Million
Managers
Name Title Age Since
Scott Richards Chief Executive Officer, MD & Executive Director 56 2012
Peter Paltoglou Chief Financial Officer - 2020
Gerard G. Nahum, Dr. Chief Medical Officer - -
Keith Moore Vice President-Research & Development - -
Ian Frank Scholes Deputy Chairman 65 2021
Bruce G. Robinson, Dr. Independent Non-Executive Director 63 2014
Nancy Dolan Independent Non-Executive Director 68 2016
Frank C. Condella Chairman 66 2021
Patrick J. Blake Independent Non-Executive Director 55 2018
Lisa Pendlebury Vice President-Communications & Investor Relations - 2010
Members of the board
Name Title Age Since
Frank C. Condella Chairman 66 2021
Ian Frank Scholes Deputy Chairman 65 2021
Scott Richards Chief Executive Officer, MD & Executive Director 56 2012
Bruce G. Robinson, Dr. Independent Non-Executive Director 63 2014
Nancy Dolan Independent Non-Executive Director 68 2016
Patrick J. Blake Independent Non-Executive Director 55 2018
Carolyn J. Myers, Dr. Director 62 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,764,840,757 1,362,534,340 77.2% 0 0.0% 77.2%
Shareholders
NameEquities%
Mithra Pharmaceuticals SA 168,872,626 9.57%
Investors Mutual Ltd. 125,723,514 7.12%
Bruce Mathieson 105,577,583 5.98%
Lazard Asset Management Pacific Co. 104,006,124 5.89%
APG Asset Management NV 45,960,108 2.60%
The Vanguard Group, Inc. 38,385,937 2.18%
Dimensional Fund Advisors LP 32,733,449 1.85%
Scott Richards 32,213,061 1.83%
Norges Bank Investment Management 23,586,559 1.34%
Vanguard Investments Australia Ltd. 21,296,621 1.21%
Holdings
NameEquities%Valuation
INHIBITOR THERAPEUTICS, INC. (INTI) 204,083,227 54.2% 34,694,149 USD
HEDGEPATH PHARMACEUTICALS, INC. 5,797,102 100.0% 985,507 USD
Company contact information
Mayne Pharma Group Ltd.
1538 Main North Road
Salisbury South
Salisbury, South Australia (SA) 5106

Phone : +61.8.8209.2666
Fax : +61.8.8281.0284
Web : http://www.maynepharma.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Mayne Pharma Group Limited